RT Journal Article
SR Electronic
T1 Assessment of the Prevalence of Pulmonary Tuberculosis Patients at Nakfa Hospital from 2014-2019, Eritrea
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.11.20021279
DO 10.1101/2020.02.11.20021279
A1 Kesete, Yafet
YR 2020
UL http://medrxiv.org/content/early/2020/02/12/2020.02.11.20021279.abstract
AB Background Tuberculosis, an infectious disease, is one of the top 10 causes of death, and the leading cause from a single infectious agent M. tuberculosis. According to recent WHO estimate report, at least 3100 new TB cases occur every year in Eritrea. However, very little information is available in Eritrea related to area specific prevalence of tuberculosis and risk factors attributed to it. This is a retrospective study aimed to assess the prevalence of tuberculosis disease among patients attending at Nakfa Hospital, Eritrea.Methods A retrospective study was conducted on patients visiting Nakfa Hospital, 221km north of Asmara, Eritrea from April 2014 to March 2019. Data was extracted from secondary data sources like patient admission records and laboratory registers at Nakfa Hospital.Results A total of 1100 patients were examined for tuberculosis using acid fast staining test. The overall prevalence of smear positive pulmonary TB cases was 7.8% (86 cases out of 1100). Females (8.2%) were more prone to have a positive Tuberculosis smear than males (7.4%). According to severity of infection, 38(3.5%) of subjects were +1 positive, whereas 23(2.1%) and 24(2.2%) of patients were +2 and +3 positives respectively. The highest prevalence of pulmonary TB was observed in the adult age group of 41-60 years (11%) and a comparatively higher number of cases was recorded in age group 21-40 years (8.3%). Adults aged between 41 to 60 had a two times more likelihood to be infected with Tuberculosis than those aged below 20 years old. Moreover, pulmonary tuberculosis was highly prevalent among middle age (20-60) than any other age class in all study years (2014-2019). The pulmonary TB cases were highly predominant during the year 2014 which was 16.8% (19 of 113 subjects) whereas the almost a quarter of it (4.5%) was recorded in following year. Based on locality, the highest rate of infection was observed in Adobha (25%), a town at border of Sudan and Eritrea, in which patients who came from Adobha had 4 times more likelihood to be infected than those from Nakfa town.Conclusion This study showed Nakfa subzone has relatively increased prevalence of smear positive pulmonary tuberculosis than the average WHO estimate for the country. Therefore, appropriate policies and strategies for prevention, targeted detection of cases and treatment are required to reinforce Tuberculosis control programs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo source of funding was needed to carry out this study.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study are available from the corresponding author upon request. TBTuberculosisM.tbMycobacterium tuberculosisWHOWorld health OrganizationMDR-TBMultidrug resistant TuberculosisRR-TBRifampsin resistant Tuberculosis